These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30037288)

  • 1. Economic evaluation of typhoid - a review.
    Frempong SN; Sutton AJ; Davenport C; Barton P
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):601-607. PubMed ID: 30037288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination.
    Watson CH; Edmunds WJ
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C42-54. PubMed ID: 25921288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines.
    Luthra K; Watts E; Debellut F; Pecenka C; Bar-Zeev N; Constenla D
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S83-S95. PubMed ID: 30845334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review.
    Frempong SN; King N; Sagoo GS
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):391-397. PubMed ID: 34842022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination against typhoid fever in travellers: a cost-effectiveness approach.
    Papadimitropoulos V; Vergidis PI; Bliziotis I; Falagas ME
    Clin Microbiol Infect; 2004 Aug; 10(8):681-3. PubMed ID: 15301670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.
    Antillón M; Bilcke J; Paltiel AD; Pitzer VE
    Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typhoid fever in children.
    Bhattarai MD
    Lancet; 1999 Dec; 354(9194):2001. PubMed ID: 10622328
    [No Abstract]   [Full Text] [Related]  

  • 10. Modelling the cost-effectiveness of a rapid diagnostic test (IgMFA) for uncomplicated typhoid fever in Cambodia.
    Saito MK; Parry CM; Yeung S
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006961. PubMed ID: 30452445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating investments in typhoid vaccines in two slums in Kolkata, India.
    Cook J; Sur D; Clemens J; Whittington D
    J Health Popul Nutr; 2009 Dec; 27(6):711-24. PubMed ID: 20099754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community.
    Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ
    J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda.
    Carias C; Walters MS; Wefula E; Date KA; Swerdlow DL; Vijayaraghavan M; Mintz E
    Vaccine; 2015 Apr; 33(17):2079-85. PubMed ID: 25712333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for Typhoid Vaccination in India.
    Srinivasan M; Sindhu KN; John J; Kang G
    Indian Pediatr; 2019 Jun; 56(6):453-458. PubMed ID: 31278221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The unrecognized burden of typhoid fever.
    Obaro SK; Iroh Tam PY; Mintz ED
    Expert Rev Vaccines; 2017 Mar; 16(3):249-260. PubMed ID: 27797598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.
    Zuckerman JN; Hatz C; Kantele A
    Expert Rev Vaccines; 2017 Oct; 16(10):1029-1043. PubMed ID: 28856924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desirability for a typhoid fever vaccine among rural residents, Pemba Island, Tanzania.
    Kaljee LM; Pach A; Thriemer K; Ley B; Jiddawi M; Puri M; Ochiai L; Wierzba T; Clemens J; Ali SM
    Vaccine; 2013 Jun; 31(29):2994-9. PubMed ID: 23664993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for investing in typhoid vaccines.
    Brooks WA
    J Health Popul Nutr; 2009 Dec; 27(6):709-10. PubMed ID: 20099753
    [No Abstract]   [Full Text] [Related]  

  • 19. An optimization model for reducing typhoid cases in developing countries without increasing public spending.
    Lauria DT; Maskery B; Poulos C; Whittington D
    Vaccine; 2009 Mar; 27(10):1609-21. PubMed ID: 19146902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typhoid fever vaccines.
    Baridalyne N; Anand K; Pandav CS
    Natl Med J India; 2000; 13(2):79-80. PubMed ID: 10835854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.